LATEST FROM IPOX^®

News

News and updates from IPOX^®, including media mentions, interviews, research and press releases.

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu on ARKO Petroleum’s Nasdaq Debut and Market Volatility

ARKO Petroleum’s recent Nasdaq debut, valued at $808 million, saw shares slip 1.4% amid heightened market volatility. IPOX^® VP Kat Liu provided expert analysis on the cautious investor sentiment surrounding 2026 listings. "In the current environment, where volatility remains elevated and many IPOs have struggled to hold above their offer price, investors are definitely approaching deals with caution," Liu noted, highlighting the growing scrutiny facing new stocks in today's shifting financial landscape.

February 13, 2026Kat Liu

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer comments on Clear Street’s Slashed IPO Target

A Reuters article details Wall Street broker Clear Street’s decision to slash its IPO fundraising target by 65% amid investor caution. IPOX^® Research Associate Lukas Muehlbauer provided expert commentary, noting that recent volatility in AI-driven financial stocks and sharp declines in crypto markets likely dampened sentiment, given Clear Street's exposure to crypto treasury capital raises. The move reflects a broader trend of demanding realistic pricing for new listings.

February 12, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Associate Muehlbauer Comments on Agibank's Downsized IPO

Agibank slashed its U.S. IPO size by over 50% and lowered its price range following the poor aftermarket performance of rival PicPay. Reuters featured IPOX^® Research Associate Lukas Muehlbauer, who analyzed the valuation pressures facing the Brazilian fintech. Muehlbauer noted that while the restructured deal, now consisting solely of primary shares, allows the listing to proceed, it introduces potential stock overhang risks as existing shareholders chose to retain their positions rather than sell at lower valuations.

February 10, 2026

Media mentions · Bloomberg

Bloomberg: IPOX^® Associate Muehlbauer Featured in Coverage of Saudi IPO Retail Push

A recent Bloomberg article highlights the debate over Saudi Arabia’s push to increase retail IPO allocations to 30%. IPOX^® Associate Muehlbauer is featured, noting that high retail quotas in a recovering market may force issuers to offer steeper discounts. This post includes Muehlbauer's full commentary to Bloomberg, discussing global parallels with India’s model and the potential for these allocations to serve as "citizen dividends," while cautioning against short-term volatility risks.

February 9, 2026

Media mentions · Reuters

Reuters: IPOX^® Associate Muehlbauer on Agomab’s Nasdaq Debut Amid Biotech Selectivity

Belgium’s Agomab Therapeutics debuted on the Nasdaq with a $716 million valuation, despite shares slipping 8% amid a selective market. While biotech activity is rebounding, investor caution remains high for clinical-stage firms. IPOX^® Research Associate Lukas Muehlbauer noted that while the window for drugmakers remains open, it is effectively closed for software firms, highlighting a significant divergence in risk appetite across sectors in the current IPO landscape.

February 6, 2026

Media mentions · Reuters

Reuters: IPOX^® Associate Muehlbauer Comments on Forgent Power's NYSE Debut

Reuters highlights Forgent Power’s successful $8 billion NYSE debut, underscoring the enduring demand for AI infrastructure. IPOX^® Research Associate Lukas Muehlbauer provided expert commentary, noting that the midpoint pricing signals "healthy but disciplined investor demand" amid volatility. He emphasized Forgent’s strategic value as a critical infrastructure provider, offering unique exposure to the AI sector distinct from traditional tech firms, driven by surging data center needs.

February 5, 2026

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer comments on York Space Systems’ NYSE Debut

Reuters features IPOX^® Associate Lukas Muehlbauer’s commentary on York Space Systems’ $4.75 billion NYSE debut. Muehlbauer notes that the successful listing signals a receptive market for defense and space stocks in 2026, setting the stage for the highly anticipated SpaceX IPO. He also analyzes York’s acquisition of ATLAS Space Operations, cautioning that despite the push into software services, the stock will likely remain volatile and sensitive to government spending news in the near term.

January 29, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer analyzes Eikon Therapeutics' Strategic Positioning and IPO Launch

Reuters features IPOX^® Research Associate Lukas Muehlbauer’s analysis on Eikon Therapeutics' upcoming $908 million IPO. Muehlbauer highlights the premium placed on CEO Roger Perlmutter’s leadership and the company’s Nobel Prize-backed drug discovery platform. He further contrasts Eikon with recent listings like Aktis Oncology, explaining how Eikon aims to overcome historical toxicity challenges in immune-stimulating drugs. This listing signals renewed momentum for the biotech sector following a challenging 2025.

January 28, 2026Lukas Muehlbauer

Media mentions · Bloomberg

Bloomberg: IPOX^® CEO Josef Schuster Comments on Risks of Celebrity-Backed IPOs

Bloomberg features IPOX^® CEO Josef Schuster’s analysis on the "Once Upon a Farm" IPO, co-founded by Jennifer Garner. Discussing the "Hollywood IPO Curse," Schuster warns that celebrity-backed deals historically underperform, citing an "eight out of 11" failure rate. He urges investors to prioritize operational expertise and management resumes over star power. The article underscores the critical importance of evaluating business fundamentals versus celebrity marketing when assessing new public listings.

January 26, 2026Josef Schuster

News

Stay ahead of the next listing.